Teva Pharmaceuticals
TEVA
727 hedge funds and large institutions have $18.5B invested in Teva Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 115 funds opening new positions, 204 increasing their positions, 318 reducing their positions, and 84 closing their positions.
37% more first-time investments, than exits
New positions opened: 115 | Existing positions closed: 84
33% more call options, than puts
Call options by funds: $772M | Put options by funds: $579M
11% more capital invested
Capital invested by funds: $16.7B → $18.5B (+$1.8B)
10% more funds holding in top 10
Funds holding in top 10: 29 → 32 (+3)
3% more funds holding
Funds holding: 705 → 727 (+22)
1.99% more ownership
Funds ownership: 46.16% → 48.15% (+2%)
36% less repeat investments, than reductions
Existing positions increased: 204 | Existing positions reduced: 318
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$861M |
| 2 |
PC
PointState Capital
New York
|
+$372M |
| 3 |
SFM
Soros Fund Management
New York
|
+$225M |
| 4 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
+$212M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$204M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$540M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$419M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$163M |
| 4 |
SCM
Scopia Capital Management
New York
|
-$143M |
| 5 |
IGIM
I.G. Investment Management
Winnipeg,
Manitoba, Canada
|
-$134M |
TEVA Hedge Fund Activity: Q4 2013 in Review
727 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2013, worth a combined $18.5B — up 11% from $16.7B a quarter earlier.
Buyers outnumbered sellers: 115 funds opened new TEVA positions and 84 closed out — a net gain of 31 holders — while 204 added to existing stakes and 318 trimmed.
The largest buyer was Franklin Resources, adding an estimated $861M. The largest seller was Wellington Management Group, cutting an estimated $540M.
- 727 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2013, up from 705 in Q3 2013.
- Funds reported $18.5B of Teva Pharmaceuticals stock for Q4 2013, up 11% quarter-over-quarter.
- 115 funds opened new Teva Pharmaceuticals positions in Q4 2013 and 84 closed out, a net change of +31 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2013 was Franklin Resources, an estimated $861M added.
- The largest Teva Pharmaceuticals seller in Q4 2013 was Wellington Management Group, an estimated $540M sold.
Based on aggregated 13F filings for Q4 2013.